“新四联”引领下射血分数降低的心力衰竭的新型多靶点药物治疗进展

打开文本图片集

【Abstract】Heartfilue（HF）represents teend-stageofardovasulardiseassAcodingtoteleftventricularjectionfractioHF canbecategorizedintoseveralsubtypes.Heartfalurewithreducedejectionfraction（HFrEF）acountsforhelargestproportionandis associatedwiththemostsevereclinicaloutcomes.Despiteadvancementsinmedicationleadingtomulti-pathwaycombinedmanagemetfor HFrEFoverthasatientstillxhbitigospitalizationdaitates.Overteasaacolgicaltreatmentfos evolvedintot"QudupleedicalTrap”ra，aracterdbeintegaioofgiotesinepto-eprilysinibitorsdsoglucosecotransporter2inhibitorsintoclinicalguidelines.Thisreviewsystematicallyelaboratesonoptiizeddosingstrategiesforthe “QuadrupleMedicalTerapy”andeploresovelagets—cludigvcigatelectivemyosinactivators，onupplementsvabdine， glucagon-likepeptide-eptorgostsndrietierochlodeatafurteraeHFprgosiseiisteleatee implementatioofstandardizedarmacotherayforHFpatintsandprovideevidence-basedrecommendatiosforcombinatiogisinHF with comorbidities.

【Keywords】 Cardiovascular disease ;Heart failure with reduced ejection fraction;Drug therapy

心力衰竭（心衰）作为多种心血管疾病（cardiovasculardisease，CVD）的终末阶段，以心室充盈或射血功能障碍为特征，其中左室射血分数（leftventricular ejection fraction，LVEF） ⩽40% 的射血分数降低的心衰（heartfailurewithreduced ejection fraction，HFrEF）因高死亡率及社会经济负担成为临床防治重点。（剩余14500字）